Pharma: Clinic Roundup
Tuesday, October 23, 2012
Teva Pharmaceutical Industries Ltd., of Jerusalem, presented Phase IIa data for laquinimod in Crohn's disease showing treatment with laquinimod 0.5 mg/day gave a remission rate of 48.3 percent, compared to 15.9 percent for patients receiving placebo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.